サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439258

注射型ドラッグデリバリーデバイス - 世界市場の考察、競合情勢、市場予測（2030年）

Injectable Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
注射型ドラッグデリバリーデバイス - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の注射型ドラッグデリバリーデバイスの市場規模は、2023年に196億3,000万米ドル、2030年までに372億2,000万米ドルに達し、2024年～2030年の予測期間にCAGRで11.26％の成長が見込まれます。注射型ドラッグデリバリーデバイスの需要は主に、がん、糖尿病、心血管疾患などの慢性疾患の増加、自己注射器需要の増加、生物学的製剤およびバイオシミラー市場における増加、患者の治療へのコンプライアンスに対するニーズと需要の高まり、この分野における技術革新と技術の進歩によって成長を示しています。

注射型ドラッグデリバリーの市場力学

世界保健機関（WHO）のデータ（2022）によると、2020年に世界で乳がん226万件、肺がん221万件、大腸がん193万件、前立腺がん141万件、胃がん109万件が報告されました。

IDF Diabetes Atlasの統計（2023）によると、2021年に5億3,700万人の成人が糖尿病を患っていました。この数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。

British Heart Foundationが提供したデータ（2022）によると、2019年に全世界で約5億5,000万人（14人に1人）が心臓および循環器の疾患を患っており、これには約2億9,000万人の女性と約2億6,000万人の男性が含まれています。

したがって、その他の慢性疾患の中でもがん、糖尿病、心血管障害の罹患率の増加により化学療法やインスリンデリバリー処置が増加し、注射型ドラッグデリバリー市場の拡大が見込まれます。

しかし、ドラッグデリバリーシステムのナノ粒子に起因する特定の副作用や、先進の注射型ドラッグデリバリーデバイスに関連する高いコストが、予測期間に市場成長を制限すると予測されます。

注射型ドラッグデリバリーデバイス市場のセグメント分析

注射型ドラッグデリバリー市場の製品タイプセグメントでは、自己注射器が注射型ドラッグデリバリー市場を独占する可能性が高いです。この分野では数え切れないほどの技術革新と開発が行われてきました。自己注射器が提供するいくつかの大きな利点は、患者の使用に非常に便利であり、低コストで入手できることです。この製品は高精度のドラッグデリバリーに対応することができ、使いやすいもっとも適応性の高いデバイスを患者に公開する患者フィードバック後に構築されます。近年、患者の間でこのデバイスに対する選好が高まっています。全体として、自己注射器が提供する利点と自己投与に対する患者の意識は、これらのデバイスの市場需要の急増につながります。

複数の技術の進歩により、患者の間で自己注射器が受け入れられるようになっています。液化ガス、例えば液化ハイドロフルオロアルカン（HFA）を動力源とすることで、従来のバネ式注射器と比較していくつかの利点があります。主な利点は、注射中に一定の力が得られることです。完全な注射を達成するために、HFAを動力源とする自動注射器は、力が減衰する傾向がないため、典型的なバネ式自動注射器と比較して、より低いピーク力を必要とする傾向があります。これにより、シリンジにかかる応力が小さくなり、ドラッグデリバリー中の力の変動が小さくなります。

2019年10月、Becton Dickinsonは、自動注射器とプレフィラブルシリンジを一体化した堅牢なプラットフォームデバイスである2段階使い捨て自動注射器、BD Intevia（TM）を発売しました。このデバイスは、自己注射時の患者の使いやすさを高めるために開発されました。このような製品開発活動は、市場成長にプラスの影響を与えます。

したがって、その他の製品タイプとは対照的に自己注射器が提供するさまざまな利点により、自己注射器に対する患者の需要が増加し、自己注射器市場の急成長につながります。

当レポートでは、世界の注射型ドラッグデリバリーデバイス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 注射型ドラッグデリバリーデバイスのレポートのイントロダクション

第2章 注射型ドラッグデリバリーデバイスのエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 注射型ドラッグデリバリーデバイスの主な要因の分析

  • 注射型ドラッグデリバリーデバイス市場の促進要因
    • がん、糖尿病、心血管障害などの慢性疾患の罹患率の増加
    • 生物学的製剤とバイオシミラー市場の増加
    • 患者の治療へのコンプライアンスに対するニーズと需要の高まり
    • 技術革新と技術の進歩
  • 注射型ドラッグデリバリーデバイス市場の抑制要因と課題
    • ドラッグデリバリーシステムのナノ粒子により引き起こされる特定の副作用
    • 先進の注射型ドラッグデリバリーデバイスに関連する高いコスト
  • 注射型ドラッグデリバリーデバイス市場の機会
    • 使い捨て注射器とプレフィルドシリンジの需要の高まり

第5章 注射型ドラッグデリバリーデバイスのポーターのファイブフォース分析

第6章 注射型ドラッグデリバリーデバイスの市場レイアウト

  • 製品タイプ別
    • 自己注射器
    • 無針注射器
    • 自動注射器
    • ウェアラブルインジェクター
    • インスリンペン
  • 薬剤充填別
    • プレフィルドデバイス
    • 充填型デバイス
  • 再使用性別
    • 再使用可能なデバイス
    • 使い捨てデバイス
  • オンサイトデリバリー別
    • 筋肉内
    • 皮内
    • 皮下
  • エンドユーザー別
    • 病院
    • 専門クリニック
    • 在宅ケア環境
  • 地域別
    • 北米の注射型ドラッグデリバリーデバイスの市場規模（2021年～2030年）
    • 欧州の注射型ドラッグデリバリーデバイスの市場規模（2021年～2030年）
    • アジア太平洋の注射型ドラッグデリバリーデバイスの市場規模（2021年～2030年）
    • その他の地域の注射型ドラッグデリバリーデバイスの市場規模（2021年～2030年）

第7章 注射型ドラッグデリバリーデバイスの企業と製品のプロファイル

  • Eli Lilly and Company
  • Biocon
  • Becton, Dickinson & Company
  • West Pharmaceutical Services, Inc.
  • Johnson & Johnson
  • Antares Pharma
  • AbbVie Inc.
  • Pfizer Inc.
  • Mylan N.V.
  • Vetter Pharma-Fertigung GmbH & Co.KG
  • Emperra GmbH
  • Gerresheimer AG
  • SCHOTT AG
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Injectable Drug Delivery Devices Market in Global (2021-2030)
  • Table 3: Injectable Drug Delivery Devices Market in Global by Product Type (2021-2030)
  • Table 4: Injectable Drug Delivery Devices Market in Global by Drug Loading (2021-2030)
  • Table 5: Injectable Drug Delivery Devices Market in Global by Reusability (2021-2030)
  • Table 6: Injectable Drug Delivery Devices Market in Global by On Site Delivery (2021-2030)
  • Table 7: Injectable Drug Delivery Devices Market in Global by End-User (2021-2030)
  • Table 8: Injectable Drug Delivery Devices Market in Global by Geography (2021-2030)
  • Table 9: Injectable Drug Delivery Devices Market in North America (2021-2030)
  • Table 10: Injectable Drug Delivery Devices Market in the US (2021-2030)
  • Table 11: Injectable Drug Delivery Devices Market in Canada (2021-2030)
  • Table 12: Injectable Drug Delivery Devices Market in Mexico (2021-2030)
  • Table 13: Injectable Drug Delivery Devices Market in Europe (2021-2030)
  • Table 14: Injectable Drug Delivery Devices Market in France (2021-2030)
  • Table 15: Injectable Drug Delivery Devices Market in Germany (2021-2030)
  • Table 16: Injectable Drug Delivery Devices Market in United Kingdom (2021-2030)
  • Table 17: Injectable Drug Delivery Devices Market in Italy (2021-2030)
  • Table 18: Injectable Drug Delivery Devices Market in Spain (2021-2030)
  • Table 19: Injectable Drug Delivery Devices Market in Rest of Europe (2021-2030)
  • Table 20: Injectable Drug Delivery Devices Market in Asia-Pacific (2021-2030)
  • Table 21: Injectable Drug Delivery Devices Market in China (2021-2030)
  • Table 22: Injectable Drug Delivery Devices Market in Japan (2021-2030)
  • Table 23: Injectable Drug Delivery Devices Market in India (2021-2030)
  • Table 24: Injectable Drug Delivery Devices Market in Australia (2021-2030)
  • Table 25: Injectable Drug Delivery Devices Market in South Korea (2021-2030)
  • Table 26: Injectable Drug Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
  • Table 27: Injectable Drug Delivery Devices Market in Rest of the World (2021-2030)
  • Table 28: Injectable Drug Delivery Devices Market in Middle East (2021-2030)
  • Table 29: Injectable Drug Delivery Devices Market in Africa (2021-2030)
  • Table 30: Injectable Drug Delivery Devices Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Injectable Drug Delivery Devices Market in Global (2021-2030)
  • Figure 3: Injectable Drug Delivery Devices Market in Global by Product Type (2021-2030)
  • Figure 4: Injectable Drug Delivery Devices Market in Global by Drug Loading (2021-2030)
  • Figure 5: Injectable Drug Delivery Devices Market in Global by Reusability (2021-2030)
  • Figure 6: Injectable Drug Delivery Devices Market in Global by On Site Delivery (2021-2030)
  • Figure 7: Injectable Drug Delivery Devices Market in Global by End-User (2021-2030)
  • Figure 8: Injectable Drug Delivery Devices Market in Global by Geography (2021-2030)
  • Figure 9: Injectable Drug Delivery Devices Market in North America (2021-2030)
  • Figure 10: Injectable Drug Delivery Devices Market in the US (2021-2030)
  • Figure 11: Injectable Drug Delivery Devices Market in Canada (2021-2030)
  • Figure 12: Injectable Drug Delivery Devices Market in Mexico (2021-2030)
  • Figure 13: Injectable Drug Delivery Devices Market in Europe (2021-2030)
  • Figure 14: Injectable Drug Delivery Devices Market in France (2021-2030)
  • Figure 15: Injectable Drug Delivery Devices Market in Germany (2021-2030)
  • Figure 16: Injectable Drug Delivery Devices Market in United Kingdom (2021-2030)
  • Figure 17: Injectable Drug Delivery Devices Market in Italy (2021-2030)
  • Figure 18: Injectable Drug Delivery Devices Market in Spain (2021-2030)
  • Figure 19: Injectable Drug Delivery Devices Market in Rest of Europe (2021-2030)
  • Figure 20: Injectable Drug Delivery Devices Market in Asia-Pacific (2021-2030)
  • Figure 21: Injectable Drug Delivery Devices Market in China (2021-2030)
  • Figure 22: Injectable Drug Delivery Devices Market in Japan (2021-2030)
  • Figure 23: Injectable Drug Delivery Devices Market in India (2021-2030)
  • Figure 24: Injectable Drug Delivery Devices Market in Australia (2021-2030)
  • Figure 25: Injectable Drug Delivery Devices Market in South Korea (2021-2030)
  • Figure 26: Injectable Drug Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
  • Figure 27: Injectable Drug Delivery Devices Market in Rest of the World (2021-2030)
  • Figure 28: Injectable Drug Delivery Devices Market in Middle East (2021-2030)
  • Figure 29: Injectable Drug Delivery Devices Market in Africa (2021-2030)
  • Figure 30: Injectable Drug Delivery Devices Market in South America (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Market Opportunities
  • Figure 34: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0047

Injectable Drug Delivery Devices Market By Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors, and Insulin Pens), Drug Loading (Prefilled Injection Devices and Fillable Injection Devices), Reusability (Reusable and Disposable), Site Of Delivery (Intramuscular, Subcutaneous, and Intra Dermal), End-User (Hospitals, Specialty Clinics, and Homecare Settings), and Geography is expected to grow at a steady CAGR Forecast till 2030 owing to a rise observed in the demand for self-injectors and the rise in the incidence of chronic conditions such as cancer and diabetes amongst others

The global injectable drug delivery devices market was valued at USD 19.63 billion in 2023, growing at a CAGR of 11.26% during the forecast period from 2024 to 2030, to reach USD 37.22 billion by 2030. The demand for injectable drug delivery devices is primarily witnessing growth on account of the increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others, increase in demand for self-injectors, increase in biologics and biosimilar market, rising need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.

Injectable Drug Delivery Devices Market Dynamics:

According to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.

As per statistics by the IDF Diabetes Atlas (2023), 537 million adults were living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.

Hence, due to the rise in incidences of cancer, diabetes, and cardiovascular disorders among other chronic conditions, there will be a rise observed in the chemotherapy and insulin delivery procedures and hence the increase in the injectable drug delivery market.

However, certain side effects caused due to the nanoparticles of the drug delivery system and the high cost associated with advanced injectable drug delivery devices are expected to limit the market growth over the forecast period.

Injectable Drug Delivery Devices Market Segment Analysis:

Injectable Drug Delivery Devices Market by Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors, and Insulin Pens), Drug Loading (Prefilled Injection Devices and Fillable Injection Devices), Reusability (Reusable and Disposable), Site Of Delivery (Intramuscular, Subcutaneous, and Intra Dermal), End-User (Hospitals, Specialty Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the Injectable Drug Delivery Devices Market, self-injectors are likely to dominate the injectable drug delivery devices market. There have been innumerable innovations and developments that have taken place in this arena. Some profound advantages offered by self-injectors are that they are extremely convenient for patient use and are available at low costs. The product is built after patient feedback to expose patients to the most adaptable devices that can cater to the high precision of drug delivery and are easy to use. The preference for this device has lately increased among patients. Overall, the advantages offered by self-injectors and the awareness among patients of self-administration will lead to a surge in the market demand for these devices.

Several technological advancements have led to an increased acceptance of self-injectors among patients. The use of liquefied gas, for instance, liquefied hydrofluoroalkane (HFA), has acted as a power source presenting several advantages over the conventional spring-based injectors. The major advantage is that it tends to offer a constant force throughout the injection. To achieve full injection, the HFA-powered autoinjectors tend to require lower peak forces when compared with the typical spring autoinjector because the force does not tend to decay. This applies lower stresses on the syringe and results in a lower variation of force during drug delivery.

In October 2019, Becton Dickinson launched the two-step disposable autoinjector BD Intevia(TM), a robust platform device that combines an autoinjector and pre-fillable syringe in an integrated system. The device was developed to promote patient ease of use when self-injecting. Such product development activities are going to positively impact the market growth.

Hence, due to the various advantages offered by self-injectors in contrast to other product types, there will be an increase in demand among patients for these, leading to a surge in the self-injector market.

North America is expected to dominate the overall Injectable Drug Delivery Devices Market:

Among all the regions, North America is expected to account for the largest share of the injectable drug delivery devices market. This can be attributed to the rising numbers of chronic diseases, increasing research and developments, government initiatives to increase awareness about chronic conditions, and the rise in healthcare spending are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.

As per the figures mentioned by the American Cancer Society 2021, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in 2021. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) 2021, around 1,752,735 new cases of cancer were reported in the US in 2019. As per Globocan 2021 data, there were around 61,152 new cases of leukemia recorded in 2020 in the United States. As per the same source around 73, 652 cases of Non-Hodgkin lymphoma and 8,107 new cases of Hodgkin lymphoma were recorded in 2020 in the US.

The American Heart Association in 2021 projected that by 2035, more than 130 million US adults will have some type of heart disease.

Therefore, owing to the presence of a large patient pool in the country, the injectable drug delivery devices market is expected to bolster in the United States during the forecast period.

Injectable Drug Delivery Devices Market Key Players:

Some of the key market players operating in the injectable drug delivery devices market include Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation and others.

Recent Developmental Activities in Injectable Drug Delivery Devices Market:

On August 21, 2022, Zydus Cadila's needle-free, plasmid DNA Covid vaccine received the Drug Controller General of India (DCGI) approval.

On November 13, 2019, Stevanato and Duoject entered auto-injector collaboration for manufacturing and promoting the emergency use 'Maverick' auto-injector.

On October 21, 2019, Becton Dickinson and Company, a leading global medical technology company announced the launch of BD Intevia(TM) 1mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system.

Key Takes Away from the Injectable Drug Delivery Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global injectable drug delivery devices market.

Various opportunities available for the other competitor in the injectable drug delivery devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?

Target Audience who can be benefited from the Injectable Drug Delivery Devices Market Report Study

Injectable Drug Delivery Devices providers

Research organizations and consulting companies

Injectable Drug Delivery Devices-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders

Various End-Users who want to know more about the injectable drug delivery devices market and the latest technological developments in the injectable drug delivery devices market.

Frequently Asked Questions for Injectable Drug Delivery Devices Market:

1. What are injectable drug delivery devices?

Injectable Drug Delivery devices comprise self-injectors, needle-free, auto injectors, and others. These devices help in drug delivery at targeted areas in the body. The devices tend to allow patients for easier administration of drugs without the need for any medical assistance.

2. What is the market for global injectable drug delivery devices?

The global injectable drug delivery devices market was valued at USD 19.63 billion in 2023, growing at a CAGR of 11.26% during the forecast period from 2024 to 2030, to reach USD 37.22 billion by 2030.

3. What are the drivers for global injectable drug delivery devices?

The major drivers driving the demand for injectable drug delivery devices are the rising incidences of chronic conditions, for instance, cancer, diabetes, and cardiovascular disorders among others, an increase in the demand for self-injectors, a rise in biologics and biosimilar market and the increasing need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.

4. What are the key players operating in global injectable drug delivery devices?

Some of the key market players operating in the injectable drug delivery devices market include Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.

5. What regions have the highest share in the injectable drug delivery devices market?

North America is expected to dominate the overall injectable drug delivery devices market during the forecast period, 2024 to 2030. This domination is due to the increasing numbers of chronic diseases, rising research and developments, and increasing government initiatives to improve awareness about chronic conditions and the rise in healthcare spending.

Table of Contents

1. Injectable Drug Delivery Devices Report Introduction

2. Injectable Drug Delivery Devices Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Injectable Drug Delivery Devices Key Factors Analysis

  • 4.1. Injectable Drug Delivery Devices Market Drivers
    • 4.1.1. Increasing incidences of chronic conditions such as cancer, diabetes and cardiovascular disorders among others
    • 4.1.2. Increase in biologics and biosimilar market
    • 4.1.3. Rising need and demand for patient compliance to treatment
    • 4.1.4. Rising innovations and technological advancement
  • 4.2. Injectable Drug Delivery Devices Market Restraints and Challenges
    • 4.2.1. Certain side effects caused due to the nanoparticles of the drug delivery system
    • 4.2.2. High cost associated with advanced injectable drug delivery devices
  • 4.3. Injectable Drug Delivery Devices Market Opportunities
    • 4.3.1. Rising demand for disposable injecting devices and prefilled syringes

5. Injectable Drug Delivery Devices Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Injectable Drug Delivery Devices Market Layout

  • 6.1. By Product Type
    • 6.1.1. Self-injectors
    • 6.1.2. Needle-free Injectors
    • 6.1.3. Auto Injectors
    • 6.1.4. Wearable Injectors
    • 6.1.5. Insulin Pens
  • 6.2. By Drug Loading
    • 6.2.1. Pre filled devices
    • 6.2.2. Fillable Devices
  • 6.3. By Reusability
    • 6.3.1. Reusable Devices
    • 6.3.2. Disposable Devices
  • 6.4. By On Site Delivery
    • 6.4.1. Intramuscular
    • 6.4.2. Intradermal
    • 6.4.3. Subcutaneous
  • 6.5. By End-User
    • 6.5.1. Hospitals
    • 6.5.2. Specialty Clinics
    • 6.5.3. Home care settings
  • 6.6. By Geography
    • 6.6.1. North America Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.1.1. United States Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.1.2. Canada Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.1.3. Mexico Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.6.2. Europe Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.1. France Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.2. Germany Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.3. United Kingdom Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.4. Italy Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.5. Spain Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.6. Rest of Europe Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.6.3. Asia-Pacific Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.1. China Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.2. Japan Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.3. India Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.4. Australia Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.5. South Korea Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.6. Rest of Asia Pacific Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.6.4. Rest of the World (RoW Injectable Drug Delivery Devices Market Size in USD million (2021-2030)) Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.4.1. Middle East Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.4.2. Africa Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.4.3. South America Injectable Drug Delivery Devices Market Size in USD million (2021-2030)

7. Injectable Drug Delivery Devices Company and Product Profiles

  • 7.1. Eli Lilly and Company
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Biocon
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Becton, Dickinson & Company
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. West Pharmaceutical Services, Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. Johnson & Johnson
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Antares Pharma
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. AbbVie Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Pfizer Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Mylan N.V.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Vetter Pharma-Fertigung GmbH & Co.KG
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4 Product Listing
    • 7.10.5. Entropy
  • 7.11. Emperra GmbH
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Gerresheimer AG
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. SCHOTT AG
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Terumo Corporation
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Teva Pharmaceutical Industries Ltd
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us